Biologic and clinical observations suggest that combining imatinib with IFN-α may improve
treatment outcome in chronic myeloid leukemia (CML). We randomized newly diagnosed …

Chronic myeloid leukemia is a myeloproliferative neoplasm that occurs more prominently in
the older population, with a peak incidence at ages 45 to 85 years and a median age at …

Treatment of chronic myeloid leukemia (CML) with interferon-alpha (IFN-α) was introduced
in the early 1980s. Several clinical trials showed a survival advantage for patients treated …

The optimum treatment conditions of interferon (IFN) α therapy in chronic myeloid leukemia
(CML) are still controversial. To evaluate the role of hydroxyurea (HU) for the outcome of IFN …

The 17th meeting of the WHO Expert Committee on the Selection and Use of Essential
Medicines was held in Geneva from 23rd to 27th March 2009. The meeting was opened on …

This report makes available the findings of an international group of experts that provide
WHO with the latest scientific and technical advice in the area of product regulation. The …

This multicenter randomized phase III study was designed to compare the efficacy and
toxicity of IFNα-2c (3.5 MU/d) in combination with either araC (10mg/m2 d1-10) or …

RATIONALE: A number of collaborative trial groups developed prospective randomized
trials to compare autologous stem cell transplantation (ASCT) with non-transplant therapy …

In interferon-α (IFN) treated chronic phase chronic myeloid leukaemia (CML) patients,
survival depends on individual risk profile and achievement of a complete haematological …

A insuficiência cardíaca (IC) é a via final de muitas doenças que afetam o coração, o que
explica a sua crescente prevalência. A atenção aos pacientes com IC é um desafio pelo …